Rocket Pharmaceuticals said the Food and Drug Administration has accepted its resubmitted Biologics License Application for Kresladi, a treatment for a rare genetic immune disorder. The biotechnology ...
Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated ...
Denali Therapeutics (DNLI) announced that the FDA has extended its review timeline of the biologics license application seeking accelerated ...
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve ...
DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late ...
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, ...
(RTTNews) - Denali Therapeutics (DNLI) announced that the FDA has accepted for review the Biologics License Application seeking accelerated approval for tividenofusp alfa for the treatment of Hunter ...
Novo Nordisk aims to revolutionize diabetes care with Awiqli, a potential once-weekly insulin, resubmitted for FDA approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback